Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment source : Www.vynetherapeutics.com save search
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Published: 2023-05-01 (Crawled : 12:20) - vynetherapeutics.com
VYNE | $2.33 3.56% 3.43% 28K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
vyn202 candidate treatment therapeutics potential
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-04-07 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.33 3.56% 3.43% 28K
|
Health Technology
|
| O: 13.11%
H: 9.62%
C: -3.19%
fmx114 treatment dermatitis trial therapeutics positive phase 2b
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.33 3.56% 3.43% 28K
|
Health Technology
|
| O: -0.88%
H: 4.42%
C: -1.77%
treatment atopic dermatitis dermatitis trial enroll
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.